NS-398: Cyclooxygenase-2 independent inhibition of leukocyte priming for lipid body formation and enhanced leukotriene generation

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 67, Issue 4, 2002, Pages 237-244

  Bozza, P T ^a,b   Pacheco, P ^a   Yu, W ^a   Weller, P F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CALCIMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLYCEROL 2 ACETATE 1 OLEATE; ICOSANOID; INDOMETACIN; LEUKOTRIENE; LEUKOTRIENE B4; LIPOXYGENASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLEIC ACID; PARACETAMOL; PHORBOL 13 ACETATE 12 MYRISTATE; PIROXICAM; PROSTAGLANDIN; PROSTAGLANDIN E2; PROTEIN KINASE C ACTIVATOR; THROMBOCYTE ACTIVATING FACTOR; UNSATURATED FATTY ACID; 1 ((4 METHYLSULFONYL)PHENYL) 3 TRIFLUOROMETHYL 5 (4 FLUOROPHENYL)PYRAZOLE; 1-((4-METHYLSULFONYL)PHENYL)-3-TRIFLUOROMETHYL-5-(4-FLUOROPHENYL)PYRAZOLE; ISOENZYME; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITROBENZENE DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVITY; ENZYME SYNTHESIS; HUMAN; HUMAN CELL; LEUKOCYTE; LIPOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENETICS; LIPID METABOLISM; METABOLISM; MOUSE MUTANT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ISOENZYMES; LEUKOCYTES; LEUKOTRIENE B4; LEUKOTRIENES; LIPID METABOLISM; MICE; MICE, KNOCKOUT; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; SULFONAMIDES;

EID: 0036800164     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.2002.0425     Document Type: Article

References (36)

1. Robinson J. M., Karnovsky M. L., Karnovsky M. J. Glycogen accumulation in polymorphonuclear leukocytes, and other intracellular alterations that occur during inflammation. J Cell Biol 1982; 95: 933-942.
2. Coimbra A., Lopes-Vaz A. The presence of lipid droplets and the absence of stable sudanophilia in osmium-fixed human leukocytes. J Histochem Cytockem 1971; 19:551-557.
3. Schlesinger P. A., Stillman M. T., Peterson L. Polyarthritis with birefringent lipid within synovial fluid macrophages: Case report and ultrastructural study. Arthritis Rheum 1982; 25: 1365-1368.
4. Weinstein J. Synovial fluid leukocytosis associated with intracellular lipid inclusions. Arch Intern Med 1980; 140: 560-561.
5. Bozza P. T., Payne J. L., Morham S. G., Langenbach R., Smithies O., Weller P. F. Leukocyte lipid body formation and eicosanoid generation: Cyclooxygenase-independent inhibition by aspirin. Proc Natl Acad Sci USA 1996; 93: 11091-11096.
6. Dvorak A. M., Morgan E., Schleimer R. P., Ryeom S. W., Lichtenstein L. M., Weller P. F. Ultrastructural immunogold localization of prostaglandin endoperoxide synthase (cyclooxygenase) to nonmembrane-bound cytoplasmic lipid bodies in human lung mast cells, alveolar macrophages, type II pneumocytes and neutrophils. J Histochem Cytochem 1992; 40: 759-769.
7. Dvorak A. M., Schleimer R. P., Dvorak A. M., Lichtenstein L. M., Weller P. F. Human lung mast cell and alveolar macrophage cytoplasmic lipid bodies contain arachidonic acid and prostaglandin endoperoxide synthase (cyclooxygenase), the substrate and enzyme necessary for prostaglandin production. Int Arch Allergy Immunol 1992; 99: 208-217.
8. Dvorak A. M., Morgan E., Tzizik D. M., Weller P. F. Prostaglandin endoperoxide synthase (cyclooxygenase): Ultrastructural localization to nonmembrane-bound cytoplasmic lipid bodies in human eosinophils and murine 3T3 fibroblasts. Int Arch Allergy Immunol 1994; 105: 245-250.
9. Bozza P. T., Yu W., Penrose J. F., Morgan E. S., Dvorak A. M., Weller P. F. Eosinophil lipid bodies: Specific, inducible intracellular sites for enhanced eicosanoid formation. J Exp Med 1997; 186: 909-920.
10. Bozza P. T., Yu W., Cassara J., Weller P. F. Pathways for eosinophil lipid body induction: Differing signal transduction in cells from normal and hypereosinophilic subjects. J Leukocyte Biol 1998; 64: 563-569.
11. Yu W., Bozza P. T., Tzizik D. M., Gray J. P., Cassara J., Dvorak A. M., Weller P. F. Co-compartmentalization of MAP kinases and cytosolic PLA2 at cytoplasmic lipid bodies of U937 cells. Am J Pathol 1998; 152: 759-769.
12. Bandeira-Melo C., Phoofolo M., Weller P. F. Extranuclear lipid bodies, elicited by CCR3-mediated signaling pathways, are the sites of chemokine-enhanced leukotriene C4 production in eosinophils and basophils. J Biol Chem 2001; 276: 22 779-22787
13. Bartemes K. R., McKinney S., Gleich G. J., Kita H. Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG. J Immunol 1999;162:2982-2989.
14. Bozza P. T., Payne J. L., Goulet J. L., Weller P. F. Mechanisms of PAF-induced lipid body formation: A central role for 5-lipoxygenase in the compartmentalization of leukocyte lipids. J Exp Med 1996; 183: 1515-1525.
15. Weller P. F., Ryeom S. W., Picard S. T., Ackerman S. J., Dvorak A. M. Cytoplasmic lipid bodies of neutrophils: Formation induced by cis-unsaturated fatty acids and mediated by protein kinase C. J Cell Biol 1991; 113: 137-146.
16. Vane J. Aspirin and other anti-inflammatory drugs. Thorax 2000; 55 (Suppl 2):S3-S9.
17. Smith W. L., Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001; 107: 1491-1495.
18. Serhan C. N., Clish C. B. Aspirin triggered lipid mediators: Novel inhibitors of leucocyte trafficking. Thorax 2000; 55 (Suppl 2): S10-12.
19. Yin M. J., Yamamoto Y., Gaynor R. B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80.
20. Abramson S., Korchak H., Ludewig R., Edelson H., Haines K., Levin R. I., Herman R., Rider L., Kimmel S., Weissmann G. Modes of action of aspirin-like drugs. Proc Natl Acad Sci USA 1985; 82: 7227-7231.
21. Abramson S. Therapy with and mechanisms of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1991; 3: 336-340.
22. Villanueva M., Heckenberger R., Strobach H., Palmer M., Schror K. Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro. Br J Clin Pharmacol 1993; 35: 235-242.
23. Futaki N., Takahashi S., Yokoyama M., Arai I., Higuchi S., Otomo S. NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (Cox-2) activity in vitro. Prostaglandins 1994; 47: 55-59.
24. Futaki N., Yoshikawa K., Hamasaka Y., Arai I., Higuchi S., Iizuka H., Otomo S. NS-398, a novel non-steroidal antiinflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993; 24: 105-110.
25. Masferrer J. L., Zweifel B. S., Manning P. T., Hauser S. D., Leahy K. M., Smith W. G., Isakson P. C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-3232.
26. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91: 12 013-12 017.
27. DeWitt D. L. Cox-2-selective inhibitors: The new super aspirins. Mol Pharmacol 1999; 55: 625-631.
28. Penning, T. D., Talley J. J., Bertenshaw S. R., Carter J. S., Collins P. W., Docter S., Graneto M. J., Lee L. F., Malecha J. W., Miyashiro J. M., Rogers R. S., Rogier D. J., Yu S. S., Anderson G. D., Burton E. G., Cogburn J. N., Gregory S. A., Koboldt C. M., Perkins W. E., Seibert K., Veenhuizen A. W., Zhang Y. Y., Isakson P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: Identification of 4-[5-(4-methylphenyl)-3- (trifluoromethyl)-1H- pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997; 40: 1347-1365.
29. Morham S. G., Langenbach R., Loftin C. D., Tiano H. F., Vouloumanos N., Jennette J. C., Mahler J. F., Kluckman K. D., Ledford A., Lee C. A., Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83:473-482.
30. Weller P. F., Ackerman S. J., Nicholson-Weller A., Dvorak A. M. Cytoplasmic lipid bodies of human neutrophilic leukocytes. Am J Pathol 1989; 135: 947-959.
31. Bozza P. T., Weller P. F. Arachidonyl trifluoromethyl ketone induces lipid body formation in leukocytes. Prostaglandins, Leukot Essent Fatty Acids 2001; 64: 227-230.
32. Bandeira-Melo C., Herbst A., Weller P. F. Eotaxins. Contributing to the diversity of eosinophil recruitment and activation. Am J Respir Cell Mol Biol 2001; 24: 653-657.
33. Maloney C. G., Kutchera W. A., Albertine K. H., McIntyre T. M., Prescott S. M., Zimmerman G. A. Inflammatory agonists induce cyclooxygenase type 2 expression by human neutrophils. J Immunol 1998; 160: 1402-1410.
34. Pouliot M., Gilbert C., Borgeat P., Poubelle P. E., Bourgoin S., Creminon C., Maclouf J., McColl S. R., Naccache P. H. Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils. FASEB J 1998; 12: 1109-1123.
35. Elder D. J., Halton D. E., Crew T. E., Paraskeva C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int J Cancer 2000; 86: 553-560.
36. Marx J. Cancer research. Anti-inflammatories inhibit cancer growth - But how? Science 2001; 291: 581-582,